We raised an antiserum (Tr4) in rabbits against a basic somatomedin C-like peptide preparation. Using highImmunoreactivity somatomedin C tracer, we compared the performance of radioimmunoassays in which we used the Tr4 antiserum and a well-characterized somatomedin C antiserum distributed by the National Pituitary Agency (NPA) with that of the human placental-membrane somatomedin radioreceptor assay (RRA). In their cross reactivity towards various somatomedin-like and unrelated peptides, the two radioimmunoassay methods were almost identical, although NPA antiserum, with about fourfold higher titer than Tr4 antiserum, showed a slightly greater sensitivity for most peptides tested. 
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of antibodies directed against the whole somatomedin C molecule (4), the "C-peptide" region of IGF-1 (5), or the Cterminus of IGF-1 (6) . For this reason, the term "somato- antiserum to somatomedin C was obtained from the National Pituitary Agency. We used this antiserum as a reference against which to compare the antiserum raised in our laboratory as described below. To prepare our antiserum, we made a conjugate of 1200 zg of our somatomedin preparation and 400 jg of ovalbumin (Sigma Chemical Co.; Cohn Fraction V) with glutaraldehyde (26). After dialysis against a 9 g/L solution of NaC1, about 640 g of conjugate in 1 mL, emulsified with 1 mL of complete Freund's adjuvant, was injected at multiple sites into each of two 2-kg New Zealand White rabbits. These animals were bled at four and eight weeks, and boosted at eight weeks with 200 g of conjugate in incomplete Freund's adjuvant. Blood drawn 10 days later from one rabbit contained antibody (designated "Tr4") suitable for radioimmunoassay.
Materials and Methods

Materials
Extraction of plasma samples.
Heparinized plasma samples were stored at -20 #{176}C until used. To release somatomedins from their binding proteins, we extracted all samples with acid-ethanol according to the method of Daughaday et al. (27) , except that only 0.1 mL of each sample was extracted, other reagent volumes being adjusted proportionally.
For centrifuging extracts we used a Beckman Microfuge B. Analytical recovery of somatomedin by this method is essentially complete (27). Extracts so prepared are diluted sevenfold as compared with the original plasma.
Radioimmunoassays.
The assay with use of National Pituitary Agency antiserum is referred to throughout as "NPA RIA," that with use of antiserum Tr4 as "Tr4 RIA." Incubations and separations were performed as described elsewhere (25). We used antisera at 40 000-fold final dilution for the NPA RIA and 10 000-fold final for the Tr4 RIA, giving 25-30% binding of tracer in the absence of added sample or standard. The standard was an acid-ethanol extract, prepared identically to the extracts of patients' samples, of a normal human plasma pool (n = 6), assigned a potency of 1.0 arb. unit/mL. This was included in each assay at eight dose levels between 0.1 and 25 zL per tube. Acid-ethanol extracts of patients' samples were measured in duplicate at two dose levels, 50 L and 100 L of a 50-fold dilution in assay buffer. Standard curves were prepared by linear regression of logit-transformed data. Under these conditions the useful working range of both assays was 0.1 to 10 arb. unit/mL.
Radioreceptor assay (RRA).
This assay involving the use of human placental membrane receptors was performed by our previously described modification (18) of the method of Marshall et al. (14) , except that the tracer used (5000 cpm per tube) was the same as that used for radioimmunoassay. The placental-membrane preparation (150 zg of protein per tube) bound 30-35% of tracer in the absence of added sample or standard. The standard human plasma extract was run at eight dose levels between 0.25 and 50 tL per tube. We measured acid-ethanol extracts of patients' samples in duplicate at two dose levels, 50 tL and 100 L of a 10-fold dilution in radioimmunoassay buffer. Under these conditions the useful working range was 0.1-5 arb. units/mL.
Quality control. Three plasma samples with somatomedin concentrations in the hypopituitary, normal, and acromegalic ranges were included in each assay for quality control, and were treated exactly like patients' specimens.
Overall between-assay variances were calculated from 10 assays. To gain extra degrees of freedom for determination of within-assay errors, we ran extra replicate tubes of the control specimens in some assays. Data were combined by analysis of variance to eliminate between-assay effects, to give within-assay error estimates with 23 degrees of freedom at each dose level. We used an HP 9845 computer to construct precision profiles from within-assay error measurements, by the method of Baxter (29) .
Results
Specificity
We evaluated the specificities of the three assay methods by measuring the displacement of bound somatomedin tracer by various related preparations ( Figure 1 ). Of the peptides tested, the human somatomedin preparation (2000 arb. units/mg) was the most potent in all assays, causing 50% dig. placement at a mean concentration of 0.35 ng per tube (NPA RIA), 0.55 ng per tube (Tr4 RIA), or 6 ng per tube (RRA). In most cases, parallel curves were obtained with rat somatomedin, acid-ethanol extracted human plasma pool, and MSA, although rat somatomedin showed some deviation from parallelism at high concentration in the Tr4 RIA. Rat somato- Values are expressed in arb. units/mL as means ± SO, with CV in parentheses. Between-assay errors are derived from means of duplicate determinations on control specimens assayed In 10 successive rtns. WIthin-assay errors represent the error of a single measurement, and are pooled by analysis of variance from six assays In which between 2 and 12 replicates were run. To compare wIth between-assay errors, divide values by the square root of 2.
Medium medin was more potent than MSA by RIA, but this order was reversed by RRA. The potency ratios for human somatomodin/rat somatomedin/MSA (measured at 50% displacement) were about 1/0.13/0.03 (for NPA RIA), 1/0.17/0.02 (for Tr4 RIA), and 1/0.05/0.5 (for RRA). Human insulin displaced in a non-parallel manner, but was about 25 000-fold less potent than the human somatomedin preparation with use of NPA antiserum, 50 000-fold less potent with use of Tr4 antiserum, and 250-fold less potent in the RRA. Human and ovine somatotropin, human and ovine prolactin, epidermal growth factor, fibroblast growth factor, and somatomedin B were without effect in the radioimmunoassays, while fibroblast growth factor at 1 g per tube and epidermal growth factor at 2.5 tg per tube caused approximately 15% displacement of tracer in the RRA. IGF-1, IGF-2, and somatomedin A were not available for testing.
Quality Control
Measured over 10 runs for each method, the standard acid-ethanol extracted plasma pool (a sevenfold dilution of the original pool) caused 50% displacement of bound tracer somatomedin at 1.26 (SD 0.26) iL per tube for the NPA RIA, 2.20 (SD 0.52) L per tube for the Tr4 RIA, and 17.4 (SD 2.5) tL per tube for the RRA, a reflection of the relative sensitivities of the three assays towards purified somatomedin. Table 1A shows total between-assay variation for three quality-control specimens in the three assay methods. As observed with patients' specimens (see below), the hypopituitary (low) control consistently gave a higher value by RRA than by radioimmunoassay, while the reverse was true of the acromegalic (high) specimen. Although the betweenassay CVs do not differ significantly among these methods, RRA is evidently the least-precise method in the hypopituitary range, while the Tr4 RIA was least precise for the acromegalic specimen.
Within-assay errors are shown in Table lB . These errors represent the error in measurement for a single determination, as obtained by pooling data from several assays by using analysis of variance.
The errors for means of duplicates are obtained by dividing by the square root of 2. Clearly, within-assay errors account for most of the total between-assay variation in all assay methods. Because the acid-ethanol extraction was carried out only once for each specimen and thus could not contribute to within-assay errors, we conclude that the extraction of samples is not a major 
Within-assay
CVs exceed 10% at dose levels below approximately 1.5 arb. unit/mL for the RRA, 0.3 arb. unit/mL for the NPA RIA, and even lower for the Tr4 RIA.
Patients' Samples Figure 3 shows results for plasma somatomedin measurements on 16 had somatomedin concentrations ranging from low to normal in the three assays (Table 3) . Mean values were significantly lower than normal in all cases, about 30% lower by radioimmunoassay and The RRA on average gave lower values than those obtained by radioimmunoassay, 30% lower than NPA RIA, and 38% lower than Tr4 RIA. As shown in Table 2D Because values for most specimens fall in the range 0-2 arb. units/mL, linear regression on raw data becomes biased by the relatively few acromegalic samples. Therefore we repeated the analysis on log-transformed data to give more equal weighting to values across the analytical range. Table 4B shows that, while the correlation coefficient for the comparison of radioimmunoassays increased slightly to 0.979, values for the RRA-radioimmunoassay comparisons both fell to 0.836, reflecting poorer correlations between these assay methods in the normal and low ranges.
Relationships between results obtained in the three assays can be seen clearly in Figure 5 , in which log-transformed data are plotted.
Discussion
In the past few years there has been a growing awareness of the importance of somatomedin measurement in the diagnosis and treatment of growth-hormone-related disorders. This has led to the development of radioimmunoassays in several laboratories, but none currently is available as a The data were plotted, and the correlation coeffIcients (r) determined, after log-transformation commercial kit, although one highly specific, well-characterized antiserum is distributed by the National Pituitary Agency in limited quantities.
Here we have described our evaluation of a somatomedin antiserum generated in our laboratory. The evaluation is based both on the performance of the antiserum towards plasma samples from patients with acromegaly, hypopituitarism, hypothyroidism, and renal failure, and on a comparison of the performance of this antiserum with that of the well-characterized antiserum described above. Because a human placental membrane preparation is much easier to prepare than an antiserum, we have also examined whether a radioreceptor assay involving the use of human placental receptors could provide a satisfactory alternative for laboratories in which antisera are not available.
A and normal samples, because the increase in immunoreactive somatomedin C on extraction was 1.6-fold for hypopituitary samples but almost threefold for normal samples (27). We find this method to be technically undemanding and of satisfactory reproducibility, and have used it on all samples described in this paper.
In its activity toward various peptides and towards extracts of normal and pathological plasma samples, antiserum Tr4 was analytically indistinguishable from the National Pituitary Agency antiserum throughout this evaluation. Because the latter antiserum is known to be specific for somatomedin -C/IGF-1, we assume that antiserum Tr4 has the same specificity. Therefore the assay involving Tr4 and tracer of high somatomedin C immunoreactivity (25) may be described as a somatomedin C/IGF-1 radioimmunoassay.
Final confirmation of this designation, however, will require that pure somatomedin C and IGF-1 be tested in this system. Two differences, neither of analytical significance, were seen between the NPA RIA and the Tr4 RIA. First, the NPA RIA is approximately twice as sensitive towards both purified somatomedin and extracted normal plasma pool. Second, the Tr4 RIA showed a slight upward bias as compared with the NPA RIA in samples from normal persons and from hypopituitary and renal-failure patients, but not acromegalic patients. Despite this, there was no overlap between normal and acromegalic values in either assay. The lower values obtained for hypopituitary samples with the NPA RIA meant that five of 13 values in this study were unmeasurably low. If required, accurate values could be assigned simply by increasing the sample volume, because only 1-and 2-ML volumes were measured in the present protocol.
In contrast to the two very similar antibodies, the human placental membrane RRA was analytically worse in distinguishing growth-hormone disorders, and also showed significant biases in both the hypothyroid and the renal-failure . (31) . In active acromegaly, our lack of overlap with normal values is similar to the RRA with IGF-1 as tracer (27), but contrasts with the somatomedin A RRA of Takano et al. (15) , in which some overlap was observed. However, Hall et al. (8) (38) , in contrast to the very low activity measured by bioassay (37, 39, 40) . In the present study, the radioimmunoassay methods actually gave values lower than normal for renal patients before dialysis, increasing to normal on dialysis. Even the approximately 50% higher values measured by RRA did not approach the extremely high values reported for assays in which somatomedin A is used as tracer (38) . A possible explanation for the discrepancy between radioimmunoassay and RRA results is that the RRA (and the radioimmunoassay with somatomedin A as tracer) might measure nondialyzable somatomedin fragments, or other unusual circulating forms, in renal failure that are not detected by the somatomedin C radioimmunoassay methods. The increase in somatomedin concentrations after dialysis, seen in all three assays in the present study, suggests that somatomedin synthesis may be inhibited by dialyzable circulating factors in renal failure-although hemoconcentration might also contribute to the increase in some patients.
Whether such inhibitors of somatomedin synthesis, if they exist, are similar to the postulated inhibitors of somatomedin action (37, 40) Second, the placental membrane RRA seems to measure peptides that show less growth-hormone dependence, but greater dependence upon thyroid hormones, than do those measured by the radioimmunoassay methods. Third, as evaluated by both radioimmunoassay and RRA, hemodialysis of patients with chronic renal failure causes an increase in plasma somatomedins, suggesting the removal of an inhibitor of somatomedin synthesis. Although the RRA may give results for somatomedin that are of clinical value to laboratories where an antiserum is not available, the advantages in sensitivity and specificity shown by somatomedin radioimmunoassays make them the current methods of choice for clinical use.
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